Taylan Gurgenci

Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)

J. Hardy, R. Greer, P. Good, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

‘What price do you put on your health?’: Medical cannabis, financial toxicity and patient perspectives on medication access in advanced cancer

J. Hardy, R. Olson, P. Good, 2022, Health expectations : an international journal of public participation in health care and health policy.

Research agenda for medical cannabis in palliative care

J. Hardy, P. Good, Taylan Gurgenci, 2022, BMJ Supportive & Palliative Care.

The lived experience of end-stage cardiac failure.

P. Good, Taylan Gurgenci, 2022, Australian journal of general practice.

Temporomandibular dysfunction

J. Lomas, Taylan Gurgenci, Christopher Jackson, 2018, Australian journal of general practice.

Medicinal cannabis in palliative medicine: lessons learnt from randomised controlled trials

J. Hardy, R. Olson, P. Good, 2022, BMJ Supportive & Palliative Care.

Screening for primary aldosteronism: How to adjust existing antihypertensive medications to avoid diagnostic errors.

Jun Yang, M. Wolley, Taylan Gurgenci, 2020, Australian journal of general practice.

Referral patterns and consultation locations for a novel palliative care telehealth service

A. Broadbent, Graham Grove, Taylan Gurgenci, 2023, Progress in Palliative Care.

Top Ten Tips Palliative Care Clinicians Should Know About Interpreting a Clinical Trial.

S. Mercadante, Sriram Yennu, Taylan Gurgenci, 2024, Journal of palliative medicine.

Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer—a study protocol for a randomised controlled trial

R. Mendis, Georgie Huggett, Taylan Gurgenci, 2024, Trials.